Trial Profile

Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Devimistat (Primary)
Indications Hodgkin's disease; Non-Hodgkin's lymphoma; T-cell lymphoma
Focus Adverse reactions

Most Recent Events

03 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.
08 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
05 Jun 2019 Status changed from active, no longer recruiting to completed, according to a Rafael Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com